Ardent Health Partners, LLC
NYSE:ARDTMedical - Care Facilities
-$0.14 today
- Market cap
- $2.03B
- Beta
- 0.84
- P/E (TTM)
- 9.4
- EPS (TTM)
- $0.95
Volume 7.27M
Average 0.45M
ARDT Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Ardent Health Partners, LLCNYSE: ARDT
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $32K, compared with -$30.72M a year earlier. Trailing-twelve-month accounts receivables was $89.9M.
Context
- Accounts receivables amounted to 0.9% of revenue in FY2025, up 0.3 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $32K or moves back toward the trailing-twelve-month quarterly average of $22.48M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 59.16M USD
- Year-over-year change
- +47.9%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 59.16M | +47.9% |
| FY2024 | 2024-12-31 | 40M | +122.1% |
| FY2023 | 2023-12-31 | (181.1M) | -953.9% |
| FY2022 | 2022-12-31 | (17.18M) | +82.2% |
| FY2021 | 2021-12-31 | (96.47M) | — |
Accounts Receivables vs competitors
How ARDT compares with its peers on the latest reported figures
- ARDT's LTM Mar 2026 accounts receivables of $89.9M is the largest of the 11 companies compared; the peer median is $348K.
- Its year-over-year change of +276.1% is the 2nd highest of 11, against a peer median of -35.6%.
- Accounts receivables amounts to 1.4% of revenue for ARDT, versus a peer median of 0.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $89.9M | +276.1% | — | 1.4% |
| LTM Sep 2026 | $70.85M | +52.8% | +21.4% | 2.1% | |
| LTM Mar 2026 | $45.19M | -535.3% | -4.7% | 0.8% | |
| LTM Sep 2026 | $21.58M | -22.5% | — | 11.8% | |
| LTM Jun 2026 | $19.37M | -48.7% | — | 1.2% | |
| LTM Oct 2026 | $16.53M | +166.8% | +110.8% | 0.6% | |
| LTM Sep 2026 | $14.92M | +202.5% | +50.6% | 0.5% | |
| LTM Jun 2026 | $9.98M | -1289.6% | — | 0.7% | |
| LTM Sep 2026 | $8.96M | +344.5% | -1.6% | 0.6% | |
| LTM Sep 2026 | $696K | -101.8% | — | 0.0% | |
| LTM Mar 2026 | $0 | -100.0% | -40.5% | 0.0% | |
| Peer median (excluding ARDT) | $348K | -35.6% | +9.9% | 0.6% | |
Competitors are the stored peer set for ARDT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 244.58M | 265.37M | 128.98M | 299.71M | 230.14M |
| Depreciation & Amortization | 137.2M | 138.17M | 140.84M | 146.29M | 155.7M |
| Deferred Income Tax | (30.65M) | 46.12M | 4M | 24.04M | 43.59M |
| Stock-Based Compensation | 549K | 611K | 904K | 17.98M | 39.29M |
| Change in Working Capital | (89.55M) | (9.74M) | (56.31M) | (181.75M) | (3.34M) |
| Accounts Receivables | (96.47M) | (17.18M) | (181.1M) | 40M | 59.16M |
| Inventory | (5.73M) | 4.67M | 1.67M | (9.41M) | (3.15M) |
| Accounts Payables | 109.35M | 14.42M | 136.82M | (103.86M) | 62.06M |
| Other Working Capital | (96.71M) | (11.65M) | (13.7M) | (108.49M) | (121.41M) |
| Other Non-Cash Items | (115.22M) | (478.89M) | 3.29M | 8.76M | 5.13M |
| Operating Cash Flow | 146.91M | (38.36M) | 221.7M | 315.03M | 470.51M |
| Capital Expenditures | (139M) | (151.11M) | (137.41M) | (187.51M) | (211.9M) |
| Acquisitions (Net) | (2.28M) | 206.37M | 0 | (31.25M) | (2.5M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 5.03M | (8.69M) | (575K) | (1.71M) | 179K |
| Investing Cash Flow | (136.26M) | 46.58M | (137.98M) | (220.46M) | (214.23M) |
| Debt Repayment | (84.45M) | (16.41M) | (7.03M) | (104.77M) | (7.99M) |
| Common Stock Issued | 0 | 0 | 0 | 208.66M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (62.13M) | (174.81M) | 0 | 0 | 0 |
| Other Financing Activities | (137.33M) | (79.11M) | (95.24M) | (79.24M) | (95.48M) |
| Financing Cash Flow | (283.91M) | (270.33M) | (102.26M) | 24.64M | (103.47M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (273.26M) | (262.11M) | (18.55M) | 119.21M | 152.82M |
| Free Cash Flow | 7.91M | (189.47M) | 84.29M | 127.52M | 258.61M |
Ardent Health Partners, LLC
NYSE:ARDT
Intrinsic Alpha fair value
Locked
Current Price
$14.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.